Recombinant Porcine PD-1 Fc Chimera Protein, CF

Recombinant Porcine PD-1 Fc Chimera Protein, CF Summary

Product Specifications

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: PD-1

Programmed Death-1 receptor (PD-1), also known as CD279, is type I transmembrane protein belonging to the CD28 family of immune regulatory receptors (1). Other members of this family include CD28, CTLA-4, ICOS, and BTLA (2-5). PD-1 consists of an extracellular domain (ECD) with one immunoglobulin-like V-type domain, a transmembrane domain, and a cytoplasmic region with two tyrosine resideus. These tyrosine residues form the immunoreceptor tyrosine-based inhbitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) tha are important for mediating PD-1 signaling. The extracellular domain (ECD) of porcine PD-1 shares 68% and 60% amino acid sequence identity with the human and rat PD-1, respectively. PD-1 acts as a monomeric receptor and interacts in a 1:1 stoichiometric ratio with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) (6, 7). PD-1 is expressed on activated T cells, B cells, monocytes, and dendritic cells while PD-L1 expression is constitutive on the same cells and on non-hematopoietic cells such as lung endothelial cells and hepatocytes (8, 9). Ligation of PD-L1 with PD-1 induces co-inhibitory signals on T cells promoting their apoptosis, anergy, and functional exhaustion (10). Thus, the PD-1: PD-L1 interaction is a key regulator of the threshold of immune response and peripheral immune tolerance (11). Blockade of the PD-1: PD-L1 interaction by either antibodies or genetic manipulation accelerates tumor eradication and shows potential for improving cancer immunotherapy (12-14).

Related Research Areas

• B Cell Activation
• B7/CD28 Family
• Co-stimulatory and Co-inhibitory Molecules
• Co-stimulatory Molecules Associated with Tfh Cells
• ITIM/ITAM Immunoreceptors and Related Molecules
• Natural Killer T (NKT) Cells
• Regulatory T Cells (Tregs)
• Search Immune Checkpoint Targets